

Key Drivers Underlying Positive and Negative Decisions for NICE TAs and HST Appraisals in 2023

Stothard, CA; Bodke, A; Crossley, O; Knott, C; Samuels, E; Tang, M.

[HTA130: Supplementary Materials](#)



Table 1: Included NICE TA and HST published in 2023

Reference ID	Date guidance was last updated	Title
TA937	2023-12-20	Targeted-release budesonide for treating primary IgA nephropathy
TA942	2023-12-20	Empagliflozin for treating chronic kidney disease
TA943	2023-12-19	Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes
TA755	2023-12-15	Risdiplam for treating spinal muscular atrophy
HST29	2023-12-13	Velmanase alfa for treating alpha-mannosidosis
TA939	2023-12-13	Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
TA935	2023-12-06	Secukinumab for treating moderate to severe hidradenitis suppurativa
TA934	2023-11-29	Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms
TA931	2023-11-22	Zanubrutinib for treating chronic lymphocytic leukaemia
TA930	2023-11-15	Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments
TA929	2023-11-01	Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
TA928	2023-11-02	Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
TA274	2023-11-26	Ranibizumab for treating diabetic macular oedema
TA917	2023-10-25	Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
TA924	2023-10-25	Tirzepatide for treating type 2 diabetes
TA925	2023-10-25	Mirikizumab for treating moderately to severely active ulcerative colitis
TA926	2023-10-25	Baricitinib for treating severe alopecia areata
TA919	2023-10-18	Rimegepant for treating migraine

Reference ID	Date guidance was last updated	Title
TA920	2023-10-18	Tofacitinib for treating active ankylosing spondylitis
TA921	2023-10-18	Ruxolitinib for treating polycythaemia vera
TA922	2023-10-18	Daridorexant for treating long-term insomnia
TA927	2023-10-17	Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
TA918	2023-10-11	Bimekizumab for treating axial spondyloarthritis
TA915	2023-10-04	Pegunigalsidase alfa for treating Fabry disease
TA916	2023-10-04	Bimekizumab for treating active psoriatic arthritis
HST28	2023-09-20	Birch bark extract for treating epidermolysis bullosa
TA914	2023-09-20	Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
TA913	2023-09-06	Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy
TA875	2023-09-04	Semaglutide for managing overweight and obesity
TA912	2023-08-15	Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
HST27	2023-07-26	Afamelanotide for treating erythropoietic protoporphyria
TA911	2023-07-26	Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
TA909	2023-07-12	Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer
TA906	2023-07-05	Rimegepant for preventing migraine
TA908	2023-07-05	Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
TA907	2023-06-28	Deucravacitinib for treating moderate to severe plaque psoriasis

Reference ID	Date guidance was last updated	Title
TA902	2023-06-21	Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
TA903	2023-06-21	Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer
TA904	2023-06-21	Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
TA905	2023-06-21	Upadacitinib for previously treated moderately to severely active Crohn's disease
TA900	2023-06-14	Tixagevimab plus cilgavimab for preventing COVID-19
TA898	2023-06-15	Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
TA894	2023-06-07	Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma
TA895	2023-06-07	Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
TA896	2023-06-07	Bulevirtide for treating chronic hepatitis D
TA893	2023-06-07	Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
TA897	2023-06-06	Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
TA891	2023-05-31	Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia
TA892	2023-05-31	Mosunetuzumab for treating relapsed or refractory follicular lymphoma
TA888	2023-05-17	Risankizumab for previously treated moderately to severely active Crohn's disease
TA890	2023-05-17	Difelikefalin for treating pruritus in people having haemodialysis
TA886	2023-05-10	Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
TA887	2023-05-10	Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

Reference ID	Date guidance was last updated	Title
TA881	2023-05-03	Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatment
TA882	2023-05-03	Voclosporin with mycophenolate mofetil for treating lupus nephritis
TA883	2023-05-03	Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
TA880	2023-04-21	Tezepelumab for treating severe asthma
HST25	2023-04-19	Lumasiran for treating primary hyperoxaluria type 1
HST15	2023-04-19	Onasemnogene abeparvovec for treating spinal muscular atrophy
HST26	2023-04-19	Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency
HST24	2023-04-19	Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy
TA877	2023-03-23	Finerenone for treating chronic kidney disease in type 2 diabetes
TA876	2023-03-22	Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
HST23	2023-03-01	Asfotase alfa for treating paediatric-onset hypophosphatasia
TA874	2023-03-01	Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
TA873	2023-03-01	Cannabidiol for treating seizures caused by tuberous sclerosis complex
TA871	2023-03-01	Eptinezumab for preventing migraine
TA872	2023-02-28	Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
HST22	2023-02-22	Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
TA870	2023-02-22	Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
TA868	2023-02-15	Vutrisiran for treating hereditary transthyretin-related amyloidosis

Reference ID	Date guidance was last updated	Title
TA865	2023-02-08	Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
TA866	2023-02-08	Regorafenib for previously treated metastatic colorectal cancer
TA861	2023-02-01	Upadacitinib for treating active non-radiographic axial spondyloarthritis
TA862	2023-02-01	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
TA863	2023-02-01	Somatrogon for treating growth disturbance in children and young people aged 3 years and over
TA864	2023-02-01	Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
TA860	2023-01-18	Maribavir for treating refractory cytomegalovirus infection after transplant
TA858	2023-01-11	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
TA857	2023-01-11	Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
TA856	2023-01-04	Upadacitinib for treating moderately to severely active ulcerative colitis

Abbreviations: HST: highly specialised technology; ID: identification; TA: technology appraisal.